Morepen Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.8 pts less than Nifty Microcap 250 and 5.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Morepen Laboratories reported a sharp fall in profits for Q1 FY26 (quarter ended June 30, 2025) despite relatively stable standalone revenues. On a consolidated basis, operating revenue declined about 6.6% year-on-year to Rs. 42,524 lakhs, while net profit after minority interest fell roughly 70% to Rs. 1,075 lakhs from Rs. 3,617 lakhs a year ago, dragging EPS down to Rs. 0.20 from Rs. 0.71. Standalone revenue was almost flat at Rs. 39,128 lakhs, but standalone net profit dropped about 77% to Rs. 806 lakhs as expenses and finance costs rose. The Board also approved hiving off its Medical Devices Business into Morepen Medipath Limited (a subsidiary) on a slump sale basis, flagged as a material related party transaction needing shareholder approval, set a record date of August 30, 2025 for a final dividend, and re-appointed Mr. Sanjay Suri as Whole-Time Director for three years.
Sharp profit decline and margin compression on both standalone and consolidated books signal cost pressures and weaker profitability, which is likely negative for short-term investor sentiment. However, the proposed Medical Devices hive-off, the final dividend eligibility, and the consolidation change at Dr. Morepen Limited (shareholding cut from 80% to 19.94%) are structural events shareholders should track for their effect on future earnings and balance sheet.